Clinical Trial

CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma

Name: CAR2219 CAR-T Cells for the Treatment of R/R B Cell Leukemia and Lymphoma — clinical trial record (NCT06834529)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

This is a single arm study to evaluate the safety and efficacy of CAR2219 CAR-T cells in the treatment of relapsed/refractory CD19/CD22 positive B cell Leukemia and Lymphoma.

Trial Details

NCT Number	NCT06834529
Lead Sponsor	Affiliated Hospital to Academy of Military Medical Sciences
Conditions	Relapsed or Refractory B Cell Leukemia and Lymphoma
Enrollment	20 participants
Start Date	2025-01-20
Primary Completion	2027-01-31 (estimated)
Study Completion	2027-01-31 (estimated)
Updated on ClinicalTrials.gov	2025-02-19